share_log

Cooper Companies | 10-K: FY2024 Annual Report

Cooper Companies | 10-K: FY2024 Annual Report

库珀医疗 | 10-K：2024财年年报
美股SEC公告 ·  12/07 05:25

Moomoo AI 已提取核心信息

Cooper Companies reported robust financial results for fiscal year 2024, with consolidated net sales increasing 8% to $3.90 billion. CooperVision's net sales grew 8% to $2.61 billion, driven by strong performance in toric and multifocal lenses. CooperSurgical's net sales rose 10% to $1.29 billion, bolstered by the acquisition of Cook Medical's reproductive health business.Operating income surged 32% to $705.7 million, with operating margin expanding to 18% from 15% in the previous year. The improvement was primarily due to higher sales and operational efficiencies. However, interest expense increased 9% to $114.3 million due to higher interest rates and debt balances. The effective tax rate rose to 32.6% from 28.7% in fiscal 2023.Looking ahead, Cooper Companies remains optimistic about long-term prospects in the contact lens and healthcare markets, despite facing global economic uncertainties and regulatory challenges. The company continues to focus on expanding its product portfolio, particularly in silicone hydrogel lenses and myopia management, while also pursuing growth opportunities through strategic acquisitions and market penetration in emerging regions.
Cooper Companies reported robust financial results for fiscal year 2024, with consolidated net sales increasing 8% to $3.90 billion. CooperVision's net sales grew 8% to $2.61 billion, driven by strong performance in toric and multifocal lenses. CooperSurgical's net sales rose 10% to $1.29 billion, bolstered by the acquisition of Cook Medical's reproductive health business.Operating income surged 32% to $705.7 million, with operating margin expanding to 18% from 15% in the previous year. The improvement was primarily due to higher sales and operational efficiencies. However, interest expense increased 9% to $114.3 million due to higher interest rates and debt balances. The effective tax rate rose to 32.6% from 28.7% in fiscal 2023.Looking ahead, Cooper Companies remains optimistic about long-term prospects in the contact lens and healthcare markets, despite facing global economic uncertainties and regulatory challenges. The company continues to focus on expanding its product portfolio, particularly in silicone hydrogel lenses and myopia management, while also pursuing growth opportunities through strategic acquisitions and market penetration in emerging regions.
库珀医疗报告了2024财政年度的强劲财务业绩，合并净销售额增长8%，达到39亿。库珀视光的净销售额增长8%，达到26.1亿，受益于散光和多焦点镜片的强劲表现。库珀外科的净销售额增长10%，达到12.9亿，得益于收购了Cook Medical的生育健康业务。营业收入猛增32%，达到70570万，营业利润率从去年15%扩大到18%。这一改善主要得益于销售增长和运营效率提升。然而，由于利率期货和债务余额上升，利息支出增加9%，达到11430万。有效税率从2023财政年的28.7%上升至32.6%。展望未来，尽管面临全球经济不确定性和监管挑战，库珀医疗对隐形眼镜和医疗市场的长期前景仍持乐观态度。公司继续专注于扩大其产品组合，尤其是在硅水凝胶镜片和近视管理方面，同时通过战略收购和在新兴地区的市场渗透追求增长机会。
库珀医疗报告了2024财政年度的强劲财务业绩，合并净销售额增长8%，达到39亿。库珀视光的净销售额增长8%，达到26.1亿，受益于散光和多焦点镜片的强劲表现。库珀外科的净销售额增长10%，达到12.9亿，得益于收购了Cook Medical的生育健康业务。营业收入猛增32%，达到70570万，营业利润率从去年15%扩大到18%。这一改善主要得益于销售增长和运营效率提升。然而，由于利率期货和债务余额上升，利息支出增加9%，达到11430万。有效税率从2023财政年的28.7%上升至32.6%。展望未来，尽管面临全球经济不确定性和监管挑战，库珀医疗对隐形眼镜和医疗市场的长期前景仍持乐观态度。公司继续专注于扩大其产品组合，尤其是在硅水凝胶镜片和近视管理方面，同时通过战略收购和在新兴地区的市场渗透追求增长机会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Avinger
    AVGR
    -- 1.4500
    中进医疗
    ZJYL
    -- 0.980
    Predictive Oncology
    POAI
    -- 0.7460
    Sharps Technology
    STSS
    -- 2.010
    美华国际
    MHUA
    -- 0.348

    解锁榜首股票